Page 42 - Trials Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The ring has finally arrived! By Shobha Shukla - CNS JAN 29, 2021 You guessed it right. I am talking about the dapivirine vaginal ring (DPV-VR), which is one of the top advances happening in the field of microbicides. It is the first long acting prevention product whose Phase-3 randomised controlled studies have shown that using the dapivirine vaginal ring reduced the risk of HIV infection in women and long-term use was well-tolerated. The World Health Organization (WHO) has just recommended it as a new prevention choice for women at substantial risk of HIV infection as part of combination ...

The studies conducted jointly by the NIH -funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) showed that the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01, delivered intravenously once every eight weeks, was effective at preventing the acquisition of HIV strains that were sensitive to the antibody. This was assessed by a laboratory test that measures a virus’ susceptibility to neutralization by an antibody. Announcing the results during a press conference prior to the opening session of the meeting , Larry Corey, AMP Protocol Chair and Principal In...

Antibody infusions prevent acquisition of some HIV strains An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The studies are being co...

Wednesday, 27 January 2021, 7:57 am Results of the Antibody Mediated Prevention (AMP) studies to be presented at the IAS HIV Research for Prevention (HIVR4P // Virtual) conference. Tuesday, 26 January, 2021 (Geneva, Switzerland) — IAS – the International AIDS Society – welcomes new results from two proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081- the AMP Studies) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections. The AMP results include data from more than 4,600 participants in two studies tha...

Results will inform development of long-acting antibody-based HIV prevention tools. Scanning electromicrograph of an HIV-infected T cell. NIAID An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious ...